目的 对肠道菌群与溃疡性结肠炎相关性研究现状及趋势进行可视化分析，为其深入研究和临床应用提供参考。方法 研究数据来源于中国知网（CNKI）和Web of Science数据库，对数据库自2005—2025年的文献进行筛选。利用CiteSpace和VOSviewer软件对文献的关键词、作者、期刊、机构、国家等进行可视化分析。结果 纳入中文文献926篇，英文文献2 241篇。肠道菌群与溃疡性结肠炎相关性研究领域发文量呈波动上升的趋势，中英文文献各有29位和73位作者发文量突出，北京中医药大学和Nanjing University of Chinese Medicine（南京中医药大学）的发文量分别在中英文机构中名列前茅。发文期刊方面，中国微生态学杂志和International Journal of Biological Macromolecules分别在中英文领域的发文量处于领先地位。国家层面中国以1 242篇的发文量位居全球首位，美国以342篇发文量位居第2。中文文献中溃疡性结肠炎、肠道菌群、益生菌、美沙拉嗪、中医药、参苓白术散、炎症因子等关键词频繁出现，英文文献还聚焦于粪便微生物群移植、氧化应激、肠道屏障等。聚类和突现分析显示中文文献以炎症因子、肠黏膜屏障、扶正平溃汤、参苓白术散、方证对应等为研究热点，英文文献突出肠道屏障与菌群的相互作用、肠道微生态与代谢产物、中药复方及其活性成分通过肠道菌群对炎症性肠病的作用机制等。共现密度视图显示了美沙拉嗪、炎症、氧化应激、芍药汤、黄芩汤、粪菌移植、益生菌、肠道微生态、双歧杆菌等研究受关注较多。结论 肠道菌群与溃疡性结肠炎的相关性研究热点集中在肠道微生态、粪菌移植、中药复方及其活性成分、免疫功能、代谢组学、抗炎、肠道屏障以及抗氧化应激等作用机制的研究，随着新技术的涌现，如高通量筛选、基因编辑技术、系统生物学方法等，未来该领域需要聚焦于精准调控菌群代谢产物以恢复肠道稳态，开发基于代谢产物的生物标志物辅助溃疡性结肠炎诊断和预后评估，中医药治疗与微生态疗法结合代谢产物调节，实现溃疡性结肠炎个体化治疗。

Objective To conduct a visual analysis of the current status and trends in the correlation between gut microbiota and ulcerative colitis, providing reference for future in-depth research and clinical applications. Methods The research data was sourced from China National Knowledge Infrastructure (CNKI) and Web of Science databases, and literature from 2005 to 2025 in the databases was screened. Utilizing CiteSpace and VOSviewer software to visualize and analyze keywords, authors, journals, institutions, countries, and other aspects of literature. Results A total of 926 Chinese literature and 2 241 English literature were included. The research on the correlation between gut microbiota and ulcerative colitis has shown a fluctuating upward trend in the number of publications, with 29 and 73 authors in Chinese and English respectively. Beijing University of Chinese Medicine and Nanjing University of Chinese Medicine rank among the top institutions in both Chinese and English in terms of publication volume. In terms of publishing journals, the Chinese Journal of Microbiology and the International Journal of Biological Macromolecules are leading in terms of publication volume in both Chinese and English. At the national level, China ranks first in the world with 1 242 articles published, while the United States ranks second with 342 articles published. Keywords such as ulcerative colitis, gut microbiota, probiotics, mesalazine, traditional Chinese medicine, Shenling Baizhu San, and inflammatory factors frequently appear in Chinese literature, while English literature also focuses on fecal microbiota transplantation, oxidative stress, intestinal barrier, etc. Cluster and emergent analysis show that Chinese literature focuses on the study of inflammatory factors, intestinal mucosal barrier, Fuzheng Pingkui Tang, Shenling Baizhu San, and corresponding formulas and syndromes. English literature highlights the interaction between intestinal barrier and microbiota, intestinal microbiota and metabolites, and the mechanism of action of traditional Chinese medicine formulas and active ingredients on inflammatory bowel disease through intestinal microbiota. The co-occurrence density view shows that research on mesalazine, inflammation, oxidative stress, Shaoyao Tang, Huangqin Tang, fecal microbiota transplantation, probiotics, gut microbiota, bifidobacteria, and other related topics has received much attention. Conclusion The research hotspots on the correlation between gut microbiota and ulcerative colitis focus on the study of gut microbiota, fecal microbiota transplantation, traditional Chinese medicine formulas and active ingredients, immune function, metabolomics, anti-inflammatory, intestinal barrier, and antioxidant stress mechanisms. With the emergence of new technologies such as high-throughput screening, gene editing techniques, and systems biology methods, this field needs to focus on precise regulation of microbial metabolites to restore intestinal homeostasis, develop biomarkers based on metabolites to assist in the diagnosis and prognosis evaluation of ulcerative colitis, and combine traditional Chinese medicine treatment with microbiota therapy to regulate metabolites and achieve personalized treatment of ulcerative colitis.

G350；R285

国家自然科学基金项目（82374462）；湖南省卫建委重点指导课题（C202304138307）；湖南省中医药管理局委托课题（D2023014）